After Jefferies and B.Riley FBR gave Viewray (NASDAQ: VRAY) a Buy rating last month, the company received another Buy, this time from Mizuho Securities. Analyst Difei Yang assigned a Buy rating to Viewray today and set a price target of $12. The company’s shares closed yesterday at $9.55.
“We spoke with the new team and came away encouraged from our discussion. Their successful commercialization experience at Spectranetics Corp. should translate well at ViewRay. We maintain our $12 PT until we learn more details on the execution strategy. ViewRay also reported preliminary 2Q18 revenue of $16 mil that beat FactSet consensus of $12.5 mil and reiterated full-year 2018 revenue guidance of $80-$90 mil.”
According to TipRanks.com, Yang is a top 100 analyst with an average return of 23.8% and a 55.1% success rate. Yang covers the Healthcare sector, focusing on stocks such as Nightstar Therapeutics Limited, Alder Biopharmaceuticals, and Audentes Therapeutics.
Currently, the analyst consensus on Viewray is a Strong Buy with an average price target of $12.10, which is a 26.7% upside from current levels. In a report issued on July 20, B.Riley FBR also reiterated a Buy rating on the stock with a $13.50 price target.
Based on Viewray’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $4.81 million. In comparison, last year the company had a GAAP net loss of $8.35 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ViewRay, Inc. engages in the research, development, and manufacture of magnetic resonance imaging (MRI) system. Its product includes MRIdian, which supports image-guided radiation therapy, stereotactic radiation therapy, and radiosurgery. The company was founded by Dinara Akzhigitova on September 6, 2013 and is headquartered in Oakwood Village, OH.